A Phase 3 trial just rewrote what's possible for metastatic pancreatic cancer. Here's where China stands.
Pancreatic cancer has long been one of oncology's toughest opponents. Known as a "silent killer," it often resists treatment until it has spread, leaving patients and doctors with limited options and grim prognoses. But on April 13, 2026, Revolution Medicines announced results that are rewriting what's possible.
The company's experimental drug daraxonrasib (a next-generation, multiselective RAS (ON) inhibitor) met its primary endpoint in the Phase 3 RASolute 302 trial (NCT06625320) for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The numbers are striking:
Revolution Medicines' CEO called the results "unprecedented," noting that no drug in history has demonstrated a survival benefit of this magnitude in a Phase 3 pancreatic cancer trial. RAS inhibitors have been a longtime goal of cancer research. The RAS gene family is mutated in roughly 30% of all human cancers, including a significant proportion of pancreatic tumors.
Daraxonrasib works by locking the RAS protein in its active (ON) state, preventing the uncontrolled cell signaling that drives tumor growth. Researchers call it a "first-in-class" agent for this mechanism in pancreatic cancer.
Source: CNBC (April 13, 2026); STAT News (April 13, 2026). Trial registration: ClinicalTrials.gov NCT06625320.
China faces one of the world's highest burdens of pancreatic cancer. According to national cancer registry data, roughly 120,000 new cases are diagnosed each year, and that number has been climbing for two decades straight, driven by an aging population and shifting risk factors.
So how is China responding to this wave, and where does it stand compared to breakthroughs like daraxonrasib?
Chinese researchers have been actively pursuing RAS-targeted therapies. Institutions including Peking Union Medical College Hospital (PUMCH), Fudan University Cancer Hospital, and the Chinese Academy of Medical Sciences have run or are running clinical trials on RAS pathway inhibitors, including combination regimens with chemotherapy and immunotherapy. Most of these trials involve international collaborations or locally developed agents, but China's expanding role in global oncology research means patients at major cancer centers can increasingly access newer protocols.
Where China may hold a particular edge is in the cell therapy space. Chinese companies and hospitals have been among the world's most active in CAR-T (chimeric antigen receptor T-cell) therapy trials. For pancreatic cancer, several Chinese institutions are investigating CAR-T targets including mesothelin (MSLN), CEA, and MUC1 (antigens expressed on pancreatic tumor cells). While still largely experimental, early-phase data from Chinese groups has shown encouraging signs in terms of safety and preliminary response rates, particularly when combined with chemotherapy.
In the near term, Chinese oncologists rely on a mix of globally available targeted agents and domestically developed alternatives. For patients whose tumors carry actionable mutations (such as BRCA2, PALB2, or microsatellite instability), PARP inhibitors and immunotherapy (PD-1 inhibitors) are increasingly incorporated into treatment plans at major centers. Erlotinib (an EGFR inhibitor) remains available in combination with gemcitabine for some patients, though its benefit is modest.
Perhaps the most significant recent development for Chinese patients is better access to international clinical trials. China's National Medical Products Administration (NMPA) has simplified approvals for oncology trials, and major hospitals in Beijing, Shanghai, Guangzhou, and Chengdu now serve as trial sites for multinational studies. For patients with advanced pancreatic cancer, this opens the possibility of accessing newer drugs (including RAS inhibitors and combination immunotherapy) without traveling abroad.
| Factor | Revolution Medicines Daraxonrasib (USA) | China Today |
|---|---|---|
| Drug Type | Multiselective RAS (ON) inhibitor, first-in-class for pancreatic cancer | RAS inhibitor trials ongoing; domestic agents in earlier phases |
| Stage of Evidence | Phase 3 trial success (April 2026); NDA filing expected soon | Domestic RAS inhibitor trials mostly Phase 1/2; expanding rapidly |
| Clinical Trial Access | Available at select US and global sites; likely FDA approval 2027 | China now a trial site for multiple international studies |
| Key Treatment Options | Daraxonrasib + chemotherapy (after prior treatment failure) | Gemcitabine-based chemo + targeted therapy; CAR-T trials; immunotherapy for MSI-H |
| CAR-T Activity | Limited pancreatic CAR-T trials to date | Among world's most active CAR-T trial ecosystem; MSLN/CEA/MUC1 targets |
| Estimated Monthly Cost (if approved) | $15,000–$25,000/month (US list price, uninsured) | Domestically produced targeted drugs: ¥5,000–¥30,000/month; some covered by national insurance |
| Leading Centers | MD Anderson, Memorial Sloan Kettering (US) | PUMCH, Fudan Cancer Hospital, Sun Yat-sen University Cancer Center, Peking University Cancer Hospital |
| Patient Volume | ~60,000 new cases/year (US) | ~120,000 new cases/year (China) — roughly double the US rate |
Our coordination team can connect you with leading pancreatic cancer specialists at top Chinese cancer centers, help you understand biomarker testing, and guide you through clinical trial options.
Get a Free Consultation